Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue

Iva Stojkovska; Joseph R. Mazzulli

doi:10.1016/j.xpro.2021.100372

Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue

Iva Stojkovska, Joseph R. Mazzulli^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The accumulation of proteins into insoluble aggregates is a common feature of several neurodegenerative diseases. Aggregated α-synuclein is a major component of Lewy bodies that pathologically define Parkinson's disease (PD). Here, we present methods for the detection of pathogenic conformations of α-synuclein in induced pluripotent stem cell (iPSC) patient-derived neuron models and brain tissue. These methods can be applied to studies of PD pathogenesis and the discovery of novel therapeutics that restore physiological α-synuclein. For complete details on the use and execution of this protocol, please refer to Cuddy et al. (2019) and Zunke et al. (2018).

Original language	English (US)
Article number	100372
Journal	STAR Protocols
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/j.xpro.2021.100372
State	Published - Mar 19 2021

Keywords

Molecular biology
Neuroscience
Protein biochemistry

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Neuroscience(all)
Immunology and Microbiology(all)
Medicine(all)

Access to Document

10.1016/j.xpro.2021.100372

Cite this

@article{dd4942a266b8432683b30af069b098b3,

title = "Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue",

abstract = "The accumulation of proteins into insoluble aggregates is a common feature of several neurodegenerative diseases. Aggregated α-synuclein is a major component of Lewy bodies that pathologically define Parkinson's disease (PD). Here, we present methods for the detection of pathogenic conformations of α-synuclein in induced pluripotent stem cell (iPSC) patient-derived neuron models and brain tissue. These methods can be applied to studies of PD pathogenesis and the discovery of novel therapeutics that restore physiological α-synuclein. For complete details on the use and execution of this protocol, please refer to Cuddy et al. (2019) and Zunke et al. (2018).",

keywords = "Molecular biology, Neuroscience, Protein biochemistry",

author = "Iva Stojkovska and Mazzulli, {Joseph R.}",

note = "Funding Information: This work was supported by grants RF1NS109157 and R01NS092823 from the NINDS/NIA awarded to J.R.M. The protocols were written by J.R.M. and I.S. J.R.M. has received consulting fees from SK Biopharmaceuticals, Neuron23, Sanofi-Genzyme, and Lysosomal Therapeutics. J.R.M. has ownership/investment interests in Lysosomal Therapeutics. Funding Information: This work was supported by grants RF1NS109157 and R01NS092823 from the NINDS / NIA awarded to J.R.M. Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = mar,

day = "19",

doi = "10.1016/j.xpro.2021.100372",

language = "English (US)",

volume = "2",

journal = "STAR Protocols",

issn = "2666-1667",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue

AU - Stojkovska, Iva

AU - Mazzulli, Joseph R.

N1 - Funding Information: This work was supported by grants RF1NS109157 and R01NS092823 from the NINDS/NIA awarded to J.R.M. The protocols were written by J.R.M. and I.S. J.R.M. has received consulting fees from SK Biopharmaceuticals, Neuron23, Sanofi-Genzyme, and Lysosomal Therapeutics. J.R.M. has ownership/investment interests in Lysosomal Therapeutics. Funding Information: This work was supported by grants RF1NS109157 and R01NS092823 from the NINDS / NIA awarded to J.R.M. Publisher Copyright: © 2021 The Author(s)

PY - 2021/3/19

Y1 - 2021/3/19

N2 - The accumulation of proteins into insoluble aggregates is a common feature of several neurodegenerative diseases. Aggregated α-synuclein is a major component of Lewy bodies that pathologically define Parkinson's disease (PD). Here, we present methods for the detection of pathogenic conformations of α-synuclein in induced pluripotent stem cell (iPSC) patient-derived neuron models and brain tissue. These methods can be applied to studies of PD pathogenesis and the discovery of novel therapeutics that restore physiological α-synuclein. For complete details on the use and execution of this protocol, please refer to Cuddy et al. (2019) and Zunke et al. (2018).

AB - The accumulation of proteins into insoluble aggregates is a common feature of several neurodegenerative diseases. Aggregated α-synuclein is a major component of Lewy bodies that pathologically define Parkinson's disease (PD). Here, we present methods for the detection of pathogenic conformations of α-synuclein in induced pluripotent stem cell (iPSC) patient-derived neuron models and brain tissue. These methods can be applied to studies of PD pathogenesis and the discovery of novel therapeutics that restore physiological α-synuclein. For complete details on the use and execution of this protocol, please refer to Cuddy et al. (2019) and Zunke et al. (2018).

KW - Molecular biology

KW - Neuroscience

KW - Protein biochemistry

UR - http://www.scopus.com/inward/record.url?scp=85101957642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101957642&partnerID=8YFLogxK

U2 - 10.1016/j.xpro.2021.100372

DO - 10.1016/j.xpro.2021.100372

M3 - Article

C2 - 33733241

AN - SCOPUS:85101957642

SN - 2666-1667

VL - 2

JO - STAR Protocols

JF - STAR Protocols

IS - 1

M1 - 100372

ER -

Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this